Syndeio Biosciences Launches with $90M to Target Synaptic Dysfunction in Alzheimer's and Depression
Syndeio Biosciences launched with $90 million in funding to develop the first synapse-targeted therapeutics for neurological and psychiatric disorders affecting over one billion people globally.
GSK's Relvar Ellipta Demonstrates Superior Asthma Control in Landmark Real-World Study
The Salford Lung Study shows patients using Relvar Ellipta had double the odds of achieving improved asthma control compared to standard care treatments.